Inmaculada Ros-Madrid

Ms. Inmaculada Ros-Madrid

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
IRInmaculada Ros-Madrid
Inmaculada Ros-Madrid
Rosario Paloma Cano-MármolRosario Paloma Cano-Mármol
Rosario Paloma Cano-Mármol
MGMercedes Ferrer Gómez
Mercedes Ferrer Gómez
Bruno Ramos-MolinaBruno Ramos-Molina
Bruno Ramos-Molina
Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), exert a wide range of beneficial effects beyond glycemic control, largely mediated by their anti-inflammatory properties. Chronic low-grade inflammation is a common pathological mechanism underlying metabolic, cardiovascular, hepatic, and neurodegenerative diseases. GLP-1RAs reduce systemic and tissue-specific inflammation through both direct and indirect mechanisms, including inhibition of nuclear factor kappa B signaling, reduction of proinflammatory cytokines, and modulation of immune cell activity, such as that of macrophages and microglia. In type 2 diabetes and obesity, GLP-1RAs improve insulin sensitivity and endothelial function by attenuating inflammation. In metabolic dysfunction-associated steatotic liver disease, GLP-1RAs reduce hepatic steatosis and fibrosis by modulating inflammation in hepatocytes and Kupffer cells. In cardiovascular disease, they mitigate atherosclerosis progression and improve vascular health. GLP-1RAs also exert direct nephroprotective effects by reducing renal inflammation, oxidative stress, and glomerular hyperfiltration in both diabetic and nondiabetic models. GLP-RAs have been also associated with the preservation of cognitive and motor function. Preclinical studies suggest that these neuroprotective effects may involve the attenuation of neuroinflammation and reduced aggregation of pathological proteins. Overall, these pleiotropic actions position incretin-based therapies as promising tools for the management of complex chronic diseases with an inflammatory component.

1 September 2021 in Patient Education and Counseling
Verified
Journal Article
Closed access
BFBeatriz Febrero
Beatriz Febrero
AJAlmela-Baeza Javier
Almela-Baeza Javier
IRInmaculada Ros-Madrid
Inmaculada Ros-Madrid
MPMª Belén Pérez-Sánchez
Mª Belén Pérez-Sánchez
PCPedro Antonio Cascales-Campos
Pedro Antonio Cascales-Campos
PRPablo Ramírez
Pablo Ramírez

12 February 2024 in Surgery
Verified
Journal Article
Closed access
BFBeatriz Febrero
Beatriz Febrero
JRJuan José Ruiz-Manzanera
Juan José Ruiz-Manzanera
IRInmaculada Ros-Madrid
Inmaculada Ros-Madrid
AVAdrián Vergara
Adrián Vergara
JRJosé M. Rodríguez
José M. Rodríguez

30 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
IRInmaculada Ros-Madrid
Inmaculada Ros-Madrid
BFBeatriz Febrero
Beatriz Febrero
Rosario Paloma Cano-MármolRosario Paloma Cano-Mármol
Rosario Paloma Cano-Mármol
MFMercedes Ferrer-Gómez
Mercedes Ferrer-Gómez
JRJosé M Rodríguez
José M Rodríguez
Background/Objectives: The presence of distant metastases is the main cause of death in medullary thyroid carcinoma (MTC). However, due to the rarity of this cancer, few studies have thoroughly analyzed the variables influencing the development of distant metastases. The objective of this study was to evaluate, in patients with MTC, the factors associated with the occurrence of synchronous and metachronous distant metastases. Methods: An analytical, observational, retrospective cohort study was conducted at a tertiary hospital. Patients with histologically confirmed MTC, both sporadic and familial (MEN2 syndrome), were included. The influence of epidemiological variables, heredity, complementary tests, surgical factors, histological features, staging, and disease progression was assessed. A univariate comparative analysis was first performed, followed by a multivariate analysis using logistic regression. Results: This study included 146 patients, of whom 75% (n = 109) had familial MTC. Lymph node involvement at diagnosis was observed in 36% (n = 52). During follow-up, distant metastases developed in 14% (n = 21) of patients, including five cases present at the time of diagnosis. The median follow-up was 214 months (IQR 106–289). The presence of distant metastases was associated with an increased risk of mortality. Factors associated with distant metastases included age, calcitonin level, hereditary status, lymph node involvement, and overall stage. In multivariate analysis, the lymph node ratio (LNR) remained the only significant predictor (OR 29.124). Conclusions: Several variables were related to the presence of distant metastases. Among them, the LNR emerged as the independent predictor of both synchronous and metachronous distant metastases.

5 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Rosario Paloma Cano-MármolRosario Paloma Cano-Mármol
Rosario Paloma Cano-Mármol
IRInmaculada Ros-Madrid
Inmaculada Ros-Madrid
MAMaría Carmen Andreo-López
María Carmen Andreo-López
MMManuel Muñoz-Torres
Manuel Muñoz-Torres
Background: Hypophosphatemia is a frequently underestimated metabolic disorder, yet it can be one of the first biochemical findings in primary hyperparathyroidism (PHPT). Current diagnostic and surgical criteria for PHPT do not include serum phosphate, despite its potential value as an early marker. Case report: We report the case of a 79-year-old woman with type 2 diabetes mellitus, hypertension and osteoarthritis, followed since 2015 for persistent hypophosphatemia (0.8 mg/dL) and stress fractures. Initial calcium and vitamin D levels were normal, but PTH was elevated. Bone scintigraphy revealed multiple stress fractures, while ultrasound and sestamibi scan were inconclusive. Despite cholecalciferol and calcitriol supplementation, hypophosphatemia persisted. From 2023, progressive hypercalcemia developed (10.9 mg/dL), with sustained hypophosphatemia (1.7 mg/dL), persistently high PTH (121 pg/mL) and markedly elevated FGF-23 (1694 kRU/L). Renal phosphate wasting was demonstrated, with reduced tubular reabsorption. An 18F-fluorocholine PET-CT performed in 2024 identified two right parathyroid adenomas, establishing the diagnosis of PHPT. The patient was referred for parathyroidectomy. Conclusions: This case illustrates the diagnostic value of chronic hypophosphatemia as an early biochemical clue to PHPT, preceding hypercalcemia by nearly a decade. Recognition of this underappreciated marker may prevent delays in diagnosis and treatment.

16 January 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
MSMaria Angeles Nuñez Sanchez
Maria Angeles Nuñez Sanchez
IRInmaculada Ros-Madrid
Inmaculada Ros-Madrid
VFVE Fernández-Ruiz
VE Fernández-Ruiz
Rosario Paloma Cano-MármolRosario Paloma Cano-Mármol
Rosario Paloma Cano-Mármol
Juan José MoranteJuan José Morante
Juan José Morante
Bruno Ramos-MolinaBruno Ramos-Molina
Bruno Ramos-Molina
Background/Objectives: Obesity is an increasingly concerning public health issue due to its high prevalence and its association with multiple comorbidities. A significant proportion of patients with obesity who undergo bariatric surgery could exhibit suboptimal mid-term outcomes. This study aims to comprehensively assess anthropometric, clinical, biochemical, nutritional, and quality of life parameters in patients with severe obesity undergoing bariatric surgery, with a particular focus on outcomes at 24 months post-surgery to capture mid-term effects that may not be apparent during the first year of follow-up. Methods: A prospective study was conducted in 95 patients with obesity undergoing bariatric surgery (Roux-en Y gastric bypass; RYGB) at the Virgen de la Arrixaca University Clinical Hospital (Murcia, Spain) between 2020 and 2023. Participants were followed up at 6, 12, and 24 months after RYGB. The study incorporated anthropometric assessments (BMI, body composition via bioelectrical impedance), full biochemical profiling, dietary analysis (using a validated food frequency questionnaire), and quality of life assessment (SF-36 questionnaire). Results: Our results showed significant weight loss after the intervention, accompanied by improvements in metabolic parameters, and dietary habits. Regarding quality of life, significant improvements were observed in both the physical (baseline: 39.62%; 6 months: 52.40%; 12 months: 53.12%) and mental components (baseline: 42.08; 6 months: 53.40; 12 months: 52.14%) at 6 and 12 months post-surgery. However, our prospective 24-month follow-up revealed that, despite these initial benefits, mental health significantly declined compared with the 12-month follow-up (24 months: 46.85%). In contrast, the physical component remained relatively stable at 24 months (24 months: 50.91%). However, our prospective 24-month follow-up revealed that, despite these initial benefits, there was a decline in mental health compared to the 12-month follow-up. Conclusions: While bariatric surgery is associated with improvements in anthropometric measures and some aspects of quality of life, our findings underscore the need for continued mid-term support to address emerging challenges in mental well-being.